The Uromigos

Episode 485: ASCO GU 2026 - LITESPARK 011: Len/Belzu vs Cabo

Episode 484: ASCO GU 2026 - LITESPARK 022: Adjuvant Pembro + Belzutifan in RCC

Episode 482: ASCO GU 2026 - SUNRISE 2

Episode 483: ASCO GU 2026 - KEYNOTE B15: Neoadjuvant EVP vs Gem/Cis in Cis-eligible MIBC

Episode 480: ASCO GU 2026 - PEACE-3 and BRCAway Final OS Results

Episode 479: Does the Timing of IO Infusion Impact Clinical Outcomes? A Critical Analysis

Episode 478: Prostate Cancer Working Group 4 (PCWG 4) criteria

Episode 477: Uromigos Japan - GU Oncology 2025を総括!

Episode 476: ASCO GU 2026 Preview

Episode 475: Depth of Response and Overall Survival for IO-based Regimens in mRCC: Results of an FDA Analysis

Episode 474: Uromigos Shorts - IO-refractory Urothelial Cancer

Episode 473: Uromigos Shorts - EMBARK and BCR Prostate Cancer

Episode 472: Uromigos Shorts - Variant Histology Bladder Cancer

Episode 471: Uromigos Shorts - ADCs and BiTEs in Prostate Cancer

Episode 470: Bladder Cancer Year in Review

Episode 469: Prostate Cancer year in Review

Episode 468: RCC Year in Review

Episode 442: The History of ARPI Development in Prostate Cancer

Episode 466: #UromigosLive 2025 - Novel Therapy in mRCC

Episode 465: #UromigosLive 2025 - Adjuvant Therapy in RCC

Episode 464: #UromigosLive 2025 - The Evolving Landscape of mHSPC

Episode 459: #UromigosLive 2025 - Radioligands in Prostate Cancer

Episode 458: #UromigosLive 2025 - Mock ODAC

Episode 463: #UromigosLive 2025 Tres Uramigas: Resumen de la sesión sobre cáncer de vejiga metastásico

Episode 462 #UromigosLive 2025: Tres Uramigas - Resumen de la sesión sobre cáncer de vejiga músculo-invasivo

Episode 461: #UromigosLive 2025 -Uromigos Japan - ウロミーゴズライブ2025: 筋層浸潤膀胱がんセッションの振り返り

Episode 460 #UromigosLive 2025: Uromigos Japan - ウロミーゴズライブ2025: 転移性膀胱がんセッションの振り返り

Episode 457: #UromigosLive 2025: ADCs in Bladder Cancer

Episode 456: #UromigosLive 2025: Peri-operative Therapy for Urothlial Cancer

Episode 455: ESMO 2025 Urothelial Cancer Review

Episode 454: ESMO 2025 Prostate and Kidney Cancer Review

Episode 453: ESMO 2025 - IMvigor011

Episode 452: ESMO 2025 - DV+ toripalimab in bladder cancer

Episode 451: ESMO 2025 - PSMAddition

Episode 450: ESMO 2025 - CAPITELLO

Episode 449: ESMO 2025 - ENZARAD

Episode 448: Neoadjuvant EV/Pembro in Cis-ineligible MIBC

Episode 447: ESMO 2025 - RAMPART

Episode 446: ESMO 2025 - OPTIC and front-line RCC triplets

Episode 445: ESMO 2025 - Systemic Checkpoint Inhibition plus BCG in NMIBC (POTOMAC and ALBAN)

Episode 444: ESMO 2025 Preview - Prostate and Renal Cancer

Episode 443: ESMO 2025 Bladder Cancer Preview

Episode 441: The History of IO in Urothelial Cancer - Part 2

Episode 440: The History of IO in Urothelial Cancer - Part 1

Episode 439: Transcriptome Expression and Treatment Sensitivity in Prostate Cancer

Episode 438: The History of Testis Cancer Treatment

Episode 437: Uromigos Japan - バルバーサ (Erdafitinib)を実臨床でどう使うか！

Episode 436: The History of IO in RCC - Part 2

Episode 435: The History of IO in RCC - Part 1

Episode 434: IMPACT series - A Walk Through the History of VEGF TKI Development in RCC